| Literature DB >> 30923510 |
Kristel M Kasius1,2, Franka Claes1,3, Wim I M Verhagen1, Jan Meulstee1.
Abstract
Background: For the preoperatively often required confirmation of clinically defined carpal tunnel syndrome (CTS), sensory as well as motor nerve conduction studies can be applied. The aim of this study was to test the sensitivity of specific motor nerve conduction tests in comparison with, as well as in addition to, sensory nerve conduction tests.Entities:
Keywords: carpal tunnel syndrome; diagnostics; motor nerve conduction tests; nerve conduction studies; sensory nerve action potentials
Year: 2019 PMID: 30923510 PMCID: PMC6426775 DOI: 10.3389/fneur.2019.00149
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Clinical features in patients and reference group.
| Women | 127 (78.4%) | 30 (63.8%) |
| Age (mean ± SD, years) | 48.73 ± 13.6 | 41.04 ± 12.2 |
| Range (years) | 18–86 | 19–59 |
| Median symptom duration (months) | 12.00 | NA |
| Wrist included left/right | 73 (45.1%)/89 (54.9%) | 24 (51.1%)/23 (48.9%) |
| Sensory loss | 125 (77.2%) | – |
| Monofilament | 66 (40.7%) | – |
| Two-point discrimination | 105 (64.8%) | – |
| Weakness abductor pollicis brevis muscle | 47 (29.0%) | – |
| Weakness opponens pollicis muscle | 10 (6.2%) | – |
p ≤ 0.05.
p ≤ 0.01.
n = 87 (53.7%) bilateral complaints.
Sensory loss is defined as numbness reported by the patient at neurological examination by means of two-point discrimination and/or monofilament.
Electrophysiological features, sensitivity, and specificity.
| DIG1 (ms) | 0.16 ± 0.19 | 0.54 | 1.12 ± 0.73 | 79.4 | 97.9 | 0.899 |
| DIG4 (ms) | 0.06 ± 0.14 | 0.34 | 1.24 ± 0.95 | 85.2 | 100 | 0.943 |
| PALM3 (m/s) | 5.64 ± 5.96 | 17.6 | 25.3 ± 10.8 | 81.8 | 100 | 0.931 |
| DML-APB (ms) | 3.36 ± 0.32 | 4.0 | 5.23 ± 1.86 | 71.0 | 100 | 0.900 |
| 2L-INT (ms) | 0.08 ± 0.53 | 1.13 | 1.86 ± 1.79 | 58.2 | 95.7 | 0.874 |
| TLI-APB | 0.32 ± 0.03 | 0.25 | 0.21 ± 0.06 | 81.3 | 97.9 | 0.950 |
| TLI-LUMB | 0.39 ± 0.04 | 0.30 | 0.28 ± 0.09 | 69.5 | 95.7 | 0.858 |
| RML-APB | 2.27 ± 0.30 | 2.86 | 4.11 ± 1.80 | 73.8 | 100 | 0.911 |
| RML-LUMB | 1.99 ± 0.39 | 2.77 | 3.63 ± 1.67 | 66.9 | 95.7 | 0.860 |
Numbers may vary due to missing values or not recordable SNAPs or CMAPs.
p ≤ 0.01.
LLN applies to TLI-APB and TLI-LUMB only.
ULN, upper limit of normal; LLN, lower limit of normal; AUC, area under the curve; DIG1, sensory median-radial comparison test; DIG4, sensory median-ulnar comparison test; PALM3, sensory short segment forearm-wrist vs. wrist-to-palm segment; DML-APB, distal motor latency to the abductor pollicis brevis muscle; 2L-INT, lumbrical-interosseous comparison study; TLI-APB, terminal latency index abductor pollicis brevis muscle; TLI-LUMB, terminal latency index lumbrical muscle; RML-APB, residual motor latency abductor pollicis brevis muscle; RML-LUMB, residual motor latency lumbrical muscle.
Figure 1ROC curve nerve conduction studies. DIG1, sensory median-radial comparison test; DIG4, sensory median-ulnar comparison test; PALM3, sensory short segment forearm-wrist vs. wrist-to-palm segment; DML-APB, distal motor latency to the abductor pollicis brevis muscle; 2L-INT, lumbrical-interosseous comparison study; TLI-APB, terminal latency index abductor pollicis brevis muscle; TLI-LUMB, terminal latency index lumbrical muscle; RML-APB, residual motor latency abductor pollicis brevis muscle; RML-LUMB, residual motor latency lumbrical muscle.
Lumbrical-interosseous (2L-INT) vs. DML-APB in all patients.
| DML-APB | Normal | 45 | 2 | 0 | 47 | (29.4%) | |||
| Abnormal | 23 | 85 | 0 | 108 | (67.5%) | ||||
| CMAP not recordable | 0 | 1 | 4 | 5 | (3.1%) | ||||
| Total | 68 | (42.5%) | 88 | (55.0%) | 4 | (2.5%) | 160 | (100%) | |
2L-INT, lumbrical-interosseous comparison study; DML-APB, distal motor latency to abductor pollicis brevis muscle; CMAP, compound muscle action potential.